References
- Brem H, Piantadosi S, Burger PC, Walker M, Selker K, Vick NA, et al. Placebo controlled trial of safety and efficacy of intra-operative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 1995;345:1008–12.
- Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen 0, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997;41: 44–49.
- Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke P, et al. A phase III trial of local chemotherapy with biodegradeable carmustine (BCNU) wafers (GLIADEL® Wafer) in patients with primary malignant glioma. Neurooncol-ogy 2003;5:79–88
- MRC Brain Tumour Working Party. Prognostic factors for high grade gliomas: development of a Prognostic Index. I Neurooncol 1990;9:47— 55
- Chang SM, Barker FG, Schmidt MH, Sloan AE, Kaspar R, Phillips L, et al. Clinical trial participation among patients enrolled in the glioma outcomes project. Cancer 2002;94:2681 —7.
- Latif AZ, Signorini D, Grant R, Gregor A, Whittle IR. Application of the MRC prognostic index to patients with malignant brain tumours in Edinburgh. I Neurol Neurosurg Psychiatry 1998;64:747 —50.
- Metcalfe SE, Grant R. Biopsy versus resection for malignant glioma. Cochran Database Syst Rev 2001;3:CD002034.
- Davies FG, Freels S, Grutsch J, Barlas S, Brem H. Survival rates in patients with primary malignant brain tumours stratified by patient age and tumour histologic type; an analysis based on Surveillance, Epidemiology, and End Result (SEER) data, 1973–1991. Neurosurg 1998;88: 1–10.
- Whittle IR, Basu N, Grant R, Walker M, Gregor A. Manage-ment of patients > 60 yrs with malignant glioma: good clinical status and radiotherapy determine outcome. Br I Neurosurg 2002;16: 343–347.
- Counsell CE, Collie DA, Grant R. Incidence of intracranial tumours in the Lothian region of Scotland, 1989–90.3 Neurol Neurosurg Psychiatry 1996;61: 143–50.